U.S. court invalidates patent on Bristol hepatitis B drug
Feb 12 (Reuters) - A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.
"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said her company is considering whether to appeal the ruling by the U.S. District Court in Delaware.
- Malaysia says no evidence missing plane flew hours after losing contact |
- Rescuers seek survivors of NY building collapse; seven dead
- White House tried to mediate dispute between Senate, CIA panel: source
- Missing jet may have strayed to west, Malaysia military says |
- UPDATE 1-U.S. investigators suspect missing Malaysian plane flew for hours -WSJ